Rivaroxabankezelés mellett kialakult bal pitvari                     fülcsethrombus sikeres kezelése direkt trombininhibitorral

Szegedi, Nándor; Gellér, László; Treuer, Tamás; Merkely, Béla

doi:10.1556/650.2016.30350

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Szegedi N. и соавт. [10] описали случай у пациента 62-х лет с персистирующей ФП в анамнезе, непрерывно принимающего ривароксабан. Пациенту планировалось проведение изоляции легочных вен, но при ЧПЭхоКГ был выявлен тромб в ЛП.…”

Section: Discussionunclassified

“…В связи с отсутствием технической возможности пациентке не проводилось генетическое исследование на предмет наличия мутации в гене метилен-тетрагидрофолатредуктазы, которая, как предполагается, может влиять на эффективность прямых ингибиторов Xа фактора (апиксабана, ривароксабана, эдоксабана) [10].…”

Section: клинический случайunclassified

See 1 more Smart Citation

Thrombosis of Left Atrial Appendage During Therapy With Direct Oral Anticoagulant. Clinical Case

Daaboul

Koroleva

Кудрявцева

et al. 2018

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

The article presents a clinical observation of the left atrial appendage thrombosis in a 51-year-old female patient with a paroxysmal form of nonvalvular atrial fibrillation which occurred despite long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient’s management. The patient was admitted with recurrent symptomatic paroxysm for more than 48 hours, because of which, in accordance with the recommendations, transesophageal echocardiography was performed before an emergency rhythm restoration. Thrombus in the left atrial appendage 0.5×1.03 cm in size was detected. It was decided to refrain from the immediate restoration of the rhythm due to the very high risk of thromboembolic complications. In connection with the categorical refusal of the patient from warfarin, it was decided to replace apixaban with another direct oral anticoagulant – dabigatran 150 mg bid for a period of 4 weeks followed by performing a control transesophageal echocardiographic study. As a result, no thrombus was found on control echocardiography. The particularity of this observation is concomitant hypertrophic cardiomyopathy and diabetes mellitus type 1 in this patient.

show abstract

Section: Discussionunclassified

Section: клинический случайunclassified

Thrombosis of Left Atrial Appendage During Therapy With Direct Oral Anticoagulant. Clinical Case

Daaboul

Koroleva

Кудрявцева

et al. 2018

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

“…It will be important to determine if a better rivaroxaban dosing regimen is required to address its unique pharmacokinetic profile [15]. One study suggests a method that measures rivaroxaban's activity level in individual patients, which can be used to compare clinical variable and patient outcomes, leading to a more customizable treatment plan and dosing regimen [18]. …”

Section: Discussionmentioning

confidence: 99%

Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy

Yaghoubian

Adashek

Yaghoubian-Yazi

et al. 2017

Case Reports in Cardiology

View full text Add to dashboard Cite

We present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented with left lower extremity edema, erythema, and pain. He was subsequently started on rivaroxaban therapy for a combined treatment period of 12 months, during and after which he persisted to have evidence of a DVT. The patient's prescribed drug regimen was changed from rivaroxaban to warfarin, which demonstrated a rapid resolution of the DVTs as determined by ultrasound assessment of our patient's lower extremity veins. Rivaroxaban, a factor Xa inhibitor, is a well-known oral anticoagulant that is used for a variety of indications and has become a mainstay in the treatment of deep vein thrombosis. With the introduction and emergence of this medication in the clinic, postmarketing reports of efficacy or lack thereof are important to review. In conclusion, we anticipate that it is likely that there are other patients with DVTs who may not respond to rivaroxaban and for whom alternative anticoagulation therapies should be explored.

show abstract

Cardiomyopathy and multiple arterial thrombosis in a patient with severe tachyform atrial fibrillation after COVID-19

et al. 2021

View full text Add to dashboard Cite

We present a case of cardiomyopathy with a reduced left ventricular ejection fraction of up to 18%, multivessel arterial thrombosis in a patient who had undergone severe COVID-19 3.5 months earlier. The cardiopathy was initially considered as an outcome of SARSCoV2-induced myocarditis, but MRI with delayed gadolinium contrast revealed no fibrosis or evidence of active myocarditis. A detailed collection of the medical history showed that the duration of tachyform atrial fibrillation exceeded the 4 months indicated in the medical records. Oligosymptomatic manifestation of arrhythmia occurred 8 months earlier, the patient did not consult a physician due to epidemic conditions. Coronary angiography revealed subtotal stenosis of the anterior descending artery. Most probably, the cardiopathy was arrhythmogenic and ischemic. After achieving normosystole and coronary stenting, the left ventricular ejection fraction was 25-27%. At the first hospitalization 4 months ago, left atrial auricular thrombus was detected. After COVID-19 the patient received inadequately low dose of apixaban 5 mg per day. Three weeks after COVID-19, the patient was diagnosed with infarction of the right kidney, wall thrombosis in the abdominal aorta, thrombosis of the superficial femoral, deep femoral, popliteal, anterior tibial arteries on the left, right popliteal artery; thrombotic complications could have developed both in situ and as a result of cardioembolism. Administration of dabigatran 300 mg per day and aspirin helped to dissolve the thrombus in the left atrial auricle, improve the course of intermittent claudication, and avoid recurrent thrombotic complications. COVID-19 could contribute to the progression of atherosclerosis, more malignant course of atrial fibrillation, development of thrombosis, but coronavirus infection is not the only cause of severe disease in a patient. СOVID-19 can not only be the cause of direct lesions of the heart and vessels, but also have an indirect negative effect - to delay the detection of cardiac pathology and be the cause of its hypodiagnosis under the mask of “postcovid”.

show abstract

Rivaroxabankezelés mellett kialakult bal pitvari fülcsethrombus sikeres kezelése direkt trombininhibitorral

Cited by 3 publications

References 9 publications

Thrombosis of Left Atrial Appendage During Therapy With Direct Oral Anticoagulant. Clinical Case

Thrombosis of Left Atrial Appendage During Therapy With Direct Oral Anticoagulant. Clinical Case

Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy

Cardiomyopathy and multiple arterial thrombosis in a patient with severe tachyform atrial fibrillation after COVID-19

Contact Info

Product

Resources

About